GlassScriptPhysician profile
Charles W Gardner
NPI 1881763670
$2,576.62
in general payments reported to CMS, 2019-2025
24 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $64.34 · 2021: $102 · 2022: $164 · 2023: $483 · 2024: $846 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,772.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $484.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $461.15 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $315.14 | 2021-2025 | |
| Lilly USA, LLC | $295.15 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $258.35 | 2021-2025 | |
| Exact Sciences Corporation | $110.27 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $101.32 | 2019-2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $84.81 | 2019-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $73.38 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Sanofi Pasteur INC. | $67.57 | 2019-2023 | |
| Gilead Sciences, INC. | $46.50 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $32.53 | 2019 | |
| Allergan, INC. | $30.10 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.96 | 2024 | |
| Merck Sharp & Dohme LLC | $25.31 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $24.18 | 2025 | Bd Max System, Bd Max Instrument |
| Takeda Pharmaceuticals U.S.A., INC. | $22.74 | 2019 | |
| Hologic Sales and Service, LLC | $22.26 | 2022 | |
| Bausch Health US, LLC | $21.18 | 2023 | Aplenzin |
| Watermark Medical, INC. | $18.82 | 2024 | |
| Medtronic, INC. | $16.52 | 2024 | Intellis Adaptivestim |
| Esperion Therapeutics, INC. | $15.28 | 2025 | Nexletol |
| Amarin Pharma, INC. | $12.09 | 2020 | |
| Shield Therapeutics INC | $11.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.